Text Size

Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans

This study is currently recruiting participants.
Verified July 2011 by University of Calgary
Sponsor:
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT01407627
First received: July 29, 2011
Last updated: August 18, 2011
Last verified: July 2011
History of Changes
  Purpose

Fructose is an ingredient that is added to many of our foods. It is a cheaper, sweeter additive that can be found in everything from soda pop to yogurt to granola bars. In the last few years a significant number of studies have been published linking consumption of fructose with obesity, hypertension and more recently, kidney and cardiovascular disease.

Animal studies show a strong link between excessive ingestion of fructose and the development of kidney and cardiovascular disease mediated by the renin angiotensin system, a hormonal system whose activation is detrimental to both the kidney and the heart. There has been very little research done on the potentially pathophysiological relationship between a high fructose diet and kidney and cardiovascular disease in humans.

The investigators hypothesize that ingestion of fructose will result in upregulation of the renin angiotensin system in healthy humans.


Condition Intervention
Renin Angiotensin System
Human
Renal Hemodynamics
 Dietary Supplement: Fructose

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans

Resource links provided by NLM:

Drug Information available for: Dextrose
U.S. FDA Resources

Further study details as provided by University of Calgary:

Primary Outcome Measures:
  • Change in filtration fraction [ Time Frame: after 2 weeks of ingestion of fructose compared to baseline value ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change in blood pressure in response to angiotensin II challenge [ Time Frame: change after 2 weeks of fructose ingestion ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: July 2011
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fructose First
  1. Study Day 1 - measurement of renal hemodynamics and blood pressure
  2. Subjects will ingest fructose 200g daily x 14d
  3. Study Day 2 - measurement of renal hemodynamics
  4. Minimum 1 week "washout" period
  5. Subjects will ingest dextrose 200g daily x 14d
  6. Study Day 3 - measurement of renal hemodynamics and blood pressure
 Dietary Supplement: Fructose

Subjects will be randomized to one of 2 sequences:

Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Active Comparator: Dextrose First
  1. Study Day 1 - measurement of renal hemodynamics and blood pressure
  2. Subjects will ingest dextrose 200g daily x 14d
  3. Study Day 2 - measurement of renal hemodynamics
  4. Minimum 1 week "washout" period
  5. Subjects will ingest fructose 200g daily x 14d
  6. Study Day 3 - measurement of renal hemodynamics and blood pressure
 Dietary Supplement: Fructose

Subjects will be randomized to one of 2 sequences:

Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age≥18 years,
  • able to comprehend study and comply with high-salt diet

Exclusion Criteria:

  • cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)
  • cerebrovascular disease (transient ischemic attacks or stroke)
  • kidney disease (estimated GFR<60 using the MDRD formula36, proteinuria or hematuria on dipstick)
  • hypertension (BP>140/90 or use of antihypertensive medications)
  • diabetes mellitus (defined by history, use of hypoglycemic agents or a fasting glucose >7mmol/L)
  • hyperlipidemia (LDL >4.5mmol/L or use of lipid-lowering agents)
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01407627

Locations
Canada, Alberta
University of Calgary Recruiting
Calgary, Alberta, Canada, T2N 2T9
Contact: Darlene Sola, RN, BScN     (403) 944-2745     dsola@ucalgary.ca    
Sponsors and Collaborators
University of Calgary
Investigators
Principal Investigator: Sofia B Ahmed, MD MMSc University of Calgary
  More Information

No publications provided

Responsible Party: Sofia Ahmed MD MMSc FRCPC, University of Calgary
ClinicalTrials.gov Identifier: NCT01407627     History of Changes
Other Study ID Numbers: UCalgary Sugar Study, AIHS, University of Calgary
Study First Received: July 29, 2011
Last Updated: August 18, 2011
Health Authority: Canada: University of Calgary Conjoint Health Research Ethics Board

Keywords provided by University of Calgary:
human
fructose
dextrose
 renin angiotensin system
kidney
renal hemodynamics

ClinicalTrials.gov processed this record on June 17, 2013